biostudies-otherUnknown14Krishna Kumar TiwariClinical cancer research : an official journal of the American Association for Cancer Research4213-4218Homo sapienshttps://www.ebi.ac.uk/biostudies/studies/MODEL0911120001biostudies-other18594002Krishna Kumar TiwariNick HolfordEléa Thibault-GreugnyLucian SmithfalseTham2008 - PDmodel, Tumour shrinkage by gemcitabine and carboplatin<notes xmlns="http://www.sbml.org/sbml/level2/version4"> <body xmlns="http://www.w3.org/1999/xhtml"> <p>PURPOSE: This tumor response pharmacodynamic model aims to describe primary lesion shrinkage in non-small cell lung cancer over time and determine if concentration-based exposure metrics for gemcitabine or that of its metabolites,n2',2'-difluorodeoxyuridine or gemcitabine triphosphate, are better than gemcitabine dose for prediction of individual response. EXPERIMENTAL DESIGN: Gemcitabine was given thrice weekly on days 1 and 8 in combination with carboplatin, which was given only on day 1 of every cycle. Gemcitabine amount in the body and area under the concentration-time curves of plasma gemcitabine, 2',2'-difluorodeoxyuridine, and intracellular gemcitabine triphosphate in white cells were compared to determine which best describes tumor shrinkage over time. Tumor growth kinetics were described using a Gompertz-like model.RESULTS: The apparent half-life for the effect of gemcitabine was 7.67 weeks. The tumor turnover time constant was 21.8 week.cm. Baseline tumor size and gemcitabine amount in the body to attain 50% of tumor shrinkage were estimated to be 6.66 cm and 10,600 mg. There was no evidence of relapse during treatment.</p> </body> </notes>2009-11-15T00:00:00Z2025-07-15T10:11:48.897Z2025-03-29T10:05:19.338ZMODEL0911120001BIOMD000000023418594002MAMO_0000046GO:0002357DOID:13249606